DeepMed Research

SANARIA INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

Phase 1

Not yet recruiting

Conditions: Malaria Falciparum

Interventions: Biological: PfSPZ-LARC2 Vaccine
Other: Normal Saline (Placebo)
Biological: PfSPZ Challenge (NF54)

First Posted Date: 2025-03-06

Last Posted Date: 2025-03-06

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 58

Registration Number: NCT06862453

Locations: 🇩🇪
University of Tubingen, Wilhelmstraße 27, Tubingen, Germany

Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

Phase 1

Recruiting

Conditions: Malaria Falciparum
Malaria Infection

Interventions: Biological: PfSPZ-LARC2 Vaccine
Biological: Normal Saline (Placebo)

First Posted Date: 2024-10-22

Last Posted Date: 2025-04-09

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 75

Registration Number: NCT06652737

Locations: 🇧🇫
Groupe de Recherche Action en Santé (GRAS) / Unité de Recherche Clinique de Sabou, Ouagadougou, Burkina Faso

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Phase 1

Terminated

Conditions: Malaria,Falciparum
Malaria

Interventions: Biological: PfSPZ Challenge (7G8)
Biological: PfSPZ Vaccine
Other: Normal Saline

First Posted Date: 2022-11-03

Last Posted Date: 2024-11-25

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 31

Registration Number: NCT05604521

Locations: 🇺🇸
University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ Vaccine
Biological: PfSPZ Challenge (7G8) for CHMI
Other: Normal Saline

First Posted Date: 2021-07-19

Last Posted Date: 2022-07-18

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 54

Registration Number: NCT04966871

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

PfSPZ Vaccine Trial in Malian Children

Phase 2

Completed

Conditions: Malaria,Falciparum
Malaria

Interventions: Biological: Sanaria® PfSPZ Vaccine
Other: Normal Saline

First Posted Date: 2021-06-25

Last Posted Date: 2024-02-07

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 290

Registration Number: NCT04940130

Locations: 🇲🇱
Malaria Research and Training Center, Bamako, Mali

Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ Vaccine
Other: Normal saline
Biological: PfSPZ Challenge (for CHMI)

First Posted Date: 2018-07-18

Last Posted Date: 2020-01-07

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 104

Registration Number: NCT03590340

Locations: 🇬🇶
Baney Clinical Research Center, Santiago De Baney, Bioko Island, Equatorial Guinea

Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children

Phase 2

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ Vaccine
Other: Normal Saline

First Posted Date: 2018-05-11

Last Posted Date: 2021-10-07

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 200

Registration Number: NCT03521973

Locations: 🇬🇦
Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Moyen-Ogooué, Gabon

Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria

Phase 2

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ Vaccine
Other: Normal Saline
Biological: PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis
Drug: Chloroquine chemoprophylaxis alone

First Posted Date: 2018-04-19

Last Posted Date: 2024-12-11

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 345

Registration Number: NCT03503058

Locations: 🇮🇩
Department of Internal Medicine, Universitas Indonesia, Jakarta, Indonesia
🇮🇩
Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Jakarta, Indonesia

Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults

Phase 1

Completed

Conditions: Malaria
Malaria,Falciparum

Interventions: Biological: PfSPZ Vaccine
Other: Normal Saline Placebo
Biological: PfSPZ Challenge

First Posted Date: 2018-02-05

Last Posted Date: 2019-04-05

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 21

Registration Number: NCT03420053

Locations: 🇹🇿
Bagamoyo Research and Training Center of the Ifakara Health Institute, Bagamoyo, Tanzania

Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ-GA1 Vaccine
Biological: PfSPZ Vaccine
Other: Normal Saline
Biological: Mosquito-bite CHMI

First Posted Date: 2017-05-22

Last Posted Date: 2019-03-05

Lead Sponsor: Sanaria Inc.

Target Recruit Count: 67

Registration Number: NCT03163121

Locations: 🇳🇱
Leiden University Medical Center, Albinusdreef 2, Leiden, Netherlands
🇳🇱
Radboud University Medical Center, Geert Grooteplein 28, Nijmegen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy